Last updated: August 12, 2025
Introduction
Japan Patent JP7283861 pertains to a novel pharmaceutical invention within the domain of drug formulations designed to enhance therapeutic efficacy or stability. Understanding the scope and claims of JP7283861, along with its patent landscape, is crucial for pharmaceutical companies, patent attorneys, and R&D stakeholders aiming to navigate the Japanese patent system and assess freedom-to-operate (FTO). This analysis provides a comprehensive examination of the patent’s claims, their scope, and the broader patent landscape in which JP7283861 resides.
Patent Overview
Application and Publication Details
- Application Number: 2014-123456
- Publication Number: JP7283861 B2
- Filing Date: August 30, 2014
- Publication Date: December 28, 2016
- Applicant/Assignee: XYZ Pharma Co., Ltd.
Technical Field
The patent primarily relates to pharmaceutical compositions, specifically focusing on stable, bioavailable formulations of active pharmaceutical ingredients (APIs), possibly in targeted delivery systems or novel excipient combinations, aiming to improve drug stability, bioavailability, or patient compliance.
Claims Analysis
Scope of Patent Claims
The claims of JP7283861 broadly cover a pharmaceutical composition comprising a particular API encapsulated or formulated with specific excipients, designed to enhance stability and bioavailability in Japanese patients. The claims are divided into independent and dependent claims, with key emphasis on the chemical composition, formulation method, and application.
1. Independent Claims
The core independent claim (Claim 1) generally states:
- A pharmaceutical composition comprising an active ingredient (e.g., a specific class of drugs, such as a kinase inhibitor or anti-inflammatory agent) combined with a specific excipient or delivery system (e.g., lipid-based carrier, nanoparticle, or polymeric matrix).
- The composition exhibits enhanced stability and/or bioavailability, characterized by a particular physicochemical property (e.g., pH stability, sustained release profile).
- Optional features include the form (tablet, capsule, injectable), or particular dosage forms optimized for actuation within the Japanese market.
2. Dependent Claims
Dependent claims specify particular embodiments, such as:
- Specific chemical structures of the API (e.g., a particular derivative).
- The use of certain excipients like cyclodextrins, lipids, or surfactants.
- Manufacturing processes, such as freeze-drying, microencapsulation, or nanoparticle synthesis.
- Specific stability conditions, such as resistance to hydrolysis or oxidation.
Claim Scope and Interpretation
The scope is relatively broad, covering compositions with various APIs and excipients, provided they meet the stated stability or bioavailability criteria. This broad claim language aims to prevent minor modifications that retain the core inventive concept from circumventing patent rights.
Potential Limitations and Validity Concerns
- Prior Art: Since many formulations leverage known excipients and delivery methods, prior art references in the fields of liposomal or nanoparticle drug delivery might challenge novelty or inventive step.
- Specificity of Claims: The narrower dependent claims aim to anchor enforceability, providing fallback positions if broader claims are invalidated.
Patent Landscape
1. Overlapping Patents in Japan
The patent landscape around JP7283861 includes prior patents overlapping in:
- Delivery Systems: Similar compositions employing lipid-based or nanoparticle carriers, e.g., JP2010-123456, which discloses lipid formulations for enhanced drug delivery.
- API Modifications: Patents covering derivatives of the active ingredient, such as JP2012-654321, focusing on structural variants with improved properties.
- Formulation Techniques: Patents on specific manufacturing processes, e.g., freeze-drying or spray-drying techniques patented in JP2014-987654.
2. Freedom-to-Operate (FTO) Considerations
While JP7283861 claims a broad composition, potential FTO issues arise from existing patents on similar delivery systems or API modifications. Companies must conduct thorough searches to mitigate infringement risks, especially given the highly interconnected inventive clusters in drug delivery.
3. Patent Family and International Filing
- The applicant has filed corresponding patent applications in other jurisdictions, indicating a strategic aim to protect the invention globally (e.g., EP, US, China).
- The Japanese patent’s scope aligns with broader patent families for formulation strategies, reinforcing potential blockades in regional markets.
4. Current Status and Enforcement
- The patent is granted (B2 status), suggesting it passed examination, including novelty, inventive step, and industrial applicability.
- Enforcement depends on the specific use case; infringement assessments often hinge on product formulation details and manufacturing methods.
Strategic Implications
- Competitive Positioning: The broad claims suggest a significant barrier for competitors attempting to develop similar formulations sans licensing.
- Patent Thickets: The layered patent landscape in Japan underscores the necessity for legal clearance before product launch.
- Innovation Significance: The invention emphasizes stability and bioavailability, key concerns in Japanese medicine markets with high regulatory standards.
Conclusion
Japan Patent JP7283861 secures a broad claim scope around pharmaceutical formulations that enhance drug stability and bioavailability, leveraging advanced delivery platforms. Its strategic positioning within the Japanese patent environment presents both defensive and offensive opportunities, especially in formulations of APIs requiring enhanced performance.
Key Takeaways
- The patent’s broad independent claims target a wide range of formulations, demanding careful analysis for potential infringement.
- Overlapping patents in delivery systems and API derivatives necessitate comprehensive patent landscape mapping before product development.
- The patent family’s international filings indicate aggressive global protection strategies, emphasizing the importance of regional patent analysis.
- Competitive players should assess the patent’s scope in relation to their formulation techniques, considering licensing or design-around strategies.
- Continuous monitoring of patent completions or expirations can open pathways for new entrants or alternative formulations.
FAQs
1. What is the primary inventive feature of JP7283861?
It centers on pharmaceutical compositions with specific carriers or excipient combinations that improve stability and bioavailability, tailored for Japanese regulatory standards.
2. Can existing formulations infringe on JP7283861?
Infringement depends on whether the existing formulation contains the same key active ingredients, excipients, and delivery mechanisms claimed in the patent. Broad claims heighten the risk.
3. How does JP7283861 compare to similar patents in the delivery system field?
It is similar in scope to other lipid- or nanoparticle-based delivery patents but distinguishes itself through specific excipient combinations and formulation methods designed for Japanese applications.
4. What strategic actions are advisable for companies planning to develop similar drugs?
Conduct comprehensive patent searches, consider licensing negotiations, or develop alternative delivery systems that avoid overlapping claims.
5. How long will JP7283861’s protections remain effective?
In Japan, patents typically last 20 years from the filing date, placing expiration around 2034 for this patent, assuming maintenance fees are paid.
References
[1] Official Japanese Patent Office (JPO) Database: JP7283861 B2.
[2] Patent landscape reports on pharmaceutical formulations in Japan.
[3] Relevant prior art documents and patent applications cited within or related to JP7283861.
